Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + sacituzumab
- Development stage
- Unknown
- Lead developer
- Shanghai Sixth People’s Hospital
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
ruxolitinib + sacituzumab is a combination therapy consisting of the Janus kinase (JAK) inhibitor ruxolitinib and the TROP2-directed antibody-drug conjugate (ADC) sacituzumab (typically administered as sacituzumab govitecan). This combination is being investigated in the "Umbrella Precision Therapy Study for Bone and Soft Tissue Sarcomas" (ChiCTR2500113769) sponsored by Shanghai Sixth People's Hospital. Ruxolitinib is a small molecule that selectively inhibits JAK1 and JAK2, which are involved in signaling pathways that regulate hematopoiesis and immune function, and is often explored in solid tumors to modulate the inflammatory tumor microenvironment. Sacituzumab govitecan consists of a humanized monoclonal antibody targeting trophoblast cell-surface antigen 2 (TROP2) conjugated to SN-38, a potent topoisomerase I inhibitor, allowing for targeted delivery of chemotherapy to TROP2-expressing sarcoma cells.
- Brand names
- JakaviTrodelvy
- Other names
- ruxolitinib phosphatesacituzumab govitecansacituzumab govitecan-hziyRuxotinib sacituzumab
02
Targets
TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)JAK3 (Janus kinase 3)
Beyond the preview
Go deeper on ruxolitinib + sacituzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + sacituzumab.